Screener
Alnylam Pharmaceuticals ALNY EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Alnylam Pharmaceuticals’s reported figures.
The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026. Open the filing →
- Filed
- Jul 30, 2026, 8:11 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001178670-26-000062
FAQ
- What is Alnylam Pharmaceuticals's EBITDA?
- Alnylam Pharmaceuticals (ALNY) reported EBITDA of $245.34M in Q2 2026.
- How has Alnylam Pharmaceuticals's EBITDA changed year-over-year?
- Alnylam Pharmaceuticals's EBITDA increased by 10979.8% year-over-year, from -$2.26M to $245.34M.
- What is the long-term trend for Alnylam Pharmaceuticals's EBITDA?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's EBITDA has grown at a -4.2% compound annual growth rate (CAGR), from -$661.09M to $557.24M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Alnylam Pharmaceuticals's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude